• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
VRTX

VRTX

Vertex Pharmaceuticals Incorporated

NASDAQHealthcareBiotechnologyUS

USD428.34

+3.25 (+0.76%)

Rating:A-

Company Profile

CEO

Reshma Kewalramani

IPO Date

1991-07-24

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$420.01

Prev. Close

$425.09

Day Low

$420.01

Day High

$429.01

52W Low

$362.50

52W High

$507.92

Market Cap

$108.72B

Volume

1.32M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

37.6%

Avg Negative

28.9%

Avg Neutral

33.5%

News Feed

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

247wallst.com·5/28/2026·↑ positive

Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

seekingalpha.com·5/19/2026·↑ positive

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

zacks.com·5/8/2026·↑ positive

Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy

seekingalpha.com·5/6/2026·↓ negative

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

businesswire.com·5/6/2026·↑ positive

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

benzinga.com·5/5/2026·↓ negative

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

zacks.com·5/5/2026·↓ negative

Breakfast News: PINS Mood Board Is Turning Bullish

fool.com·5/5/2026·↑ positive

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript

seekingalpha.com·5/4/2026·↑ positive

Vertex (VRTX) Reports Q1 Earnings: What Key Metrics Have to Say

zacks.com·5/4/2026·↑ positive